Aberrant expression and biological significance of Sox2, an embryonic stem cell transcriptional factor, in ALK-positive anaplastic large cell lymphoma

Blood Cancer Journal

Volumn 2, Issue 8, 2012, Pages

  Gelebart, P ^a   Hegazy, S A ^a   Wang, P ^a   Bone, K M ^a   Anand, M ^a   Sharon, D ^a   Hitt, M ^a   Pearson, J D ^a   Ingham, R J ^a   Ma, Y ^b   Lai, R ^a,c  

^a UNIVERSITY OF ALBERTA   (Canada)

^b STONY BROOK UNIVERSITY   (United States)

^c DynaLIFE Dx   (Canada)

Author keywords

NPM ALK; Sox2; STAT3; transcriptional activity; tumorigenicity

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; NUCLEOPHOSMIN; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR SOX2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL; CANCER INVASION; CARCINOGENICITY; CELL GROWTH; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DOWN REGULATION; HEMATOLOGIC MALIGNANCY; HUMAN; HUMAN CELL; HUMAN TISSUE; LARGE CELL LYMPHOMA; MALE; MOUSE; NONHUMAN; PATHOGENESIS; PROTEIN EXPRESSION; T LYMPHOCYTE;

EID: 84865987684     PISSN: None     EISSN: 20445385     Source Type: Journal    
DOI: 10.1038/bcj.2012.27     Document Type: Article

References (50)

1. Rizzino A. Sox2 and Oct-3/4: a versatile pair of master regulators that orchestrate the self-renewal and pluripotency of embryonic stem cells. Wiley Interdiscip Rev Syst Biol Med 2009; 1: 228-236.
2. Keramari M, Razavi J, Ingman KA, Patsch C, Edenhofer F, Ward CM et al. Sox2 is essential for formation of trophectoderm in the preimplantation embryo. PLoS One 2010; 5: e13952.
3. Bowles J, Schepers G, Koopman P. Phylogeny of the SOX family of developmental transcription factors based on sequence and structural indicators. Dev Biol 2000; 227: 239-255.
4. Wegner M. From head to toes: the multiple facets of Sox proteins. Nucleic Acids Res 1999; 27: 1409-1420. (Pubitemid 29206280)
5. Avilion AA, Nicolis SK, Pevny LH, Perez L, Vivian N, Lovell-Badge R. Multipotent cell lineages in early mouse development depend on SOX2 function. Genes Dev 2003; 17: 126-140. (Pubitemid 36062514)
6. Schneider A, Bardakjian T, Reis LM, Tyler RC, Semina EV. Novel SOX2 mutations and genotype-phenotype correlation in anophthalmia and microphthalmia. Am J Med Genet A 2009; 149A: 2706-2715.
7. Kuroda T, Tada M, Kubota H, Kimura H, Hatano SY, Suemori H et al. Octamer and Sox elements are required for transcriptional cis regulation of Nanog gene expression. Mol Cell Biol 2005; 25: 2475-2485. (Pubitemid 40354640)
8. Chew JL, Loh YH, Zhang W, Chen X, Tam WL, Yeap LS et al. Reciprocal transcriptional regulation of Pou5f1 and Sox2 via the Oct4/Sox2 complex in embryonic stem cells. Mol Cell Biol 2005; 25: 6031-6046. (Pubitemid 40946556)
9. Okumura-Nakanishi S, Saito M, Niwa H, Ishikawa F. Oct-3/4 and Sox2 regulate Oct-3/4 gene in embryonic stem cells. J Biol Chem 2005; 280: 5307-5317. (Pubitemid 40280004)
10. Sun Y, Li H, Yang H, Rao MS, Zhan M. Mechanisms controlling embryonic stem cell self-renewal and differentiation. Crit Rev Eukaryot Gene Expr 2006; 16: 211-231. (Pubitemid 44498034)
11. Sattler HP, Lensch R, Rohde V, Zimmer E, Meese E, Bonkhoff H et al. Novel amplification unit at chromosome 3q25-q27 in human prostate cancer. Prostate 2000; 45: 207-215.
12. Li XL, Eishi Y, Bai YQ, Sakai H, Akiyama Y, Tani M et al. Expression of the SRYrelated HMG box protein SOX2 in human gastric carcinoma. Int J Oncol 2004; 24: 257-263.
13. Tsukamoto T, Mizoshita T, Tatematsu M. Gastric-and-intestinal mixed-type intestinal metaplasia: aberrant expression of transcription factors and stem cell intestinalization. Gastric Cancer 2006; 9: 156-166. (Pubitemid 44426888)
14. Rodriguez-Pinilla SM, Sarrio D, Moreno-Bueno G, Rodriguez-Gil Y, Martinez MA, Hernandez L et al. Sox2: a possible driver of the basal-like phenotype in sporadic breast cancer. Mod Pathol 2007; 20: 474-481. (Pubitemid 46482371)
15. Park ET, Gum JR, Kakar S, Kwon SW, Deng G, Kim YS. Aberrant expression of SOX2 upregulates MUC5AC gastric foveolar mucin in mucinous cancers of the colorectum and related lesions. Int J Cancer 2008; 122: 1253-1260. (Pubitemid 351287224)
16. Gangemi RM, Griffero F, Marubbi D, Perera M, Capra MC, Malatesta P et al. SOX2 silencing in glioblastoma tumor-initiating cells causes stop of proliferation and loss of tumorigenicity. Stem Cells 2009; 27: 40-48.
17. Phi JH, Park SH, Kim SK, Paek SH, Kim JH, Lee YJ et al. Sox2 expression in brain tumors: a reflection of the neuroglial differentiation pathway. Am J Surg Pathol 2008; 32: 103-112.
18. Nonaka D. Differential expression of SOX2 and SOX17 in testicular germ cell tumors. Am J Clin Pathol 2009; 131: 731-736.
19. Hussenet T, Dali S, Exinger J, Monga B, Jost B, Dembele D et al. SOX2 is an oncogene activated by recurrent 3q26.3 amplifications in human lung squamous cell carcinomas. PLoS One 2010; 5: e8960.
20. Lu Y, Futtner C, Rock JR, Xu X, Whitworth W, Hogan BL et al. Evidence that SOX2 overexpression is oncogenic in the lung. PLoS One 2010; 5: e11022.
21. Schoenhals M, Kassambara A, De Vos J, Hose D, Moreaux J, Klein B. Embryonic stem cell markers expression in cancers. Biochem Biophys Res Commun 2009; 383: 157-162.
22. Delsol GFB, Muller-Hermelink HK, Campo E, Jaffe ES, Gascoyne RD, Stein H et al. Anaplastic Large Cell Lymphoma (ALCL), ALK-Positive Vol. 2. IARC: Lyon, 2008.
23. Amin HM, Lai R. Pathobiology of ALK + anaplastic large-cell lymphoma. Blood 2007; 110: 2259-2267. (Pubitemid 47523143)
24. Zamo A, Chiarle R, Piva R, Howes J, Fan Y, Chilosi M et al. Anaplastic lymphoma kinase (ALK) activates Stat3 and protects hematopoietic cells from cell death. Oncogene 2002; 21: 1038-1047. (Pubitemid 34174516)
25. Dien Bard J, Gelebart P, Anand M, Zak Z, Hegazy SA, Amin HM et al. IL-21 contributes to JAK3/STAT3 activation and promotes cell growth in ALK-positive anaplastic large cell lymphoma. Am J Pathol 2009; 175: 825-834.
26. Turner SD, Yeung D, Hadfield K, Cook SJ, Alexander DR. The NPM-ALK tyrosine kinase mimics TCR signalling pathways, inducing NFAT and AP-1 by RASdependent mechanisms. Cell Signal 2007; 19: 740-747.
27. Bai RY, Ouyang T, Miething C, Morris SW, Peschel C, Duyster J. Nucleophosminanaplastic lymphoma kinase associated with anaplastic large-cell lymphoma activates the phosphatidylinositol 3-kinase/Akt antiapoptotic signaling pathway. Blood 2000; 96: 4319-4327.
28. Amin HM, McDonnell TJ, Ma Y, Lin Q, Fujio Y, Kunisada K et al. Selective inhibition of STAT3 induces apoptosis and G(1) cell cycle arrest in ALK-positive anaplastic large cell lymphoma. Oncogene 2004; 23: 5426-5434. (Pubitemid 39044053)
29. Chiarle R, Simmons WJ, Cai H, Dhall G, Zamo A, Raz R et al. Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic target. Nat Med 2005; 11: 623-629. (Pubitemid 40868302)
30. Foshay KM, Gallicano GI. Regulation of Sox2 by STAT3 initiates commitment to the neural precursor cell fate. Stem Cells Dev 2008; 17: 269-278. (Pubitemid 351630169)
31. Pulford K, Lamant L, Morris SW, Butler LH, Wood KM, Stroud D et al. Detection of anaplastic lymphoma kinase (ALK) and nucleolar protein nucleophosmin (NPM)-ALK proteins in normal and neoplastic cells with the monoclonal antibody ALK1. Blood 1997; 89: 1394-1404. (Pubitemid 27080004)
32. Anand M, Lai R, Gelebart P. Beta-catenin is constitutively active and increases STAT3 expression/activation in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma. Haematologica 2011; 96: 253-261.
33. Gelebart P, Anand M, Armanious H, Peters AC, Dien Bard J, Amin HM et al. Constitutive activation of the Wnt canonical pathway in mantle cell lymphoma. Blood 2008; 112: 5171-5179.
34. Miyagi S, Saito T, Mizutani K, Masuyama N, Gotoh Y, Iwama A et al. The Sox-2 regulatory regions display their activities in two distinct types of multipotent stem cells. Mol Cell Biol 2004; 24: 4207-4220. (Pubitemid 41070994)
35. Tomioka M, Nishimoto M, Miyagi S, Katayanagi T, Fukui N, Niwa H et al. Identification of Sox-2 regulatory region which is under the control of Oct-3/4-Sox-2 complex. Nucleic Acids Res 2002; 30: 3202-3213. (Pubitemid 34846184)
36. Stevanovic M. Modulation of SOX2 and SOX3 gene expression during differentiation of human neuronal precursor cell line NTERA2. Mol Biol Rep 2003; 30: 127-132. (Pubitemid 36687515)
37. Ji J, Zheng PS. Expression of Sox2 in human cervical carcinogenesis. Hum Pathol 2010; 41: 1438-1447.
38. Zhang Q, Raghunath PN, Xue L, Majewski M, Carpentieri DF, Odum N et al. Multilevel dysregulation of STAT3 activation in anaplastic lymphoma kinasepositive T/null-cell lymphoma. J Immunol 2002; 168: 466-474. (Pubitemid 34014150)
39. Han Y, Amin HM, Franko B, Frantz C, Shi X, Lai R. Loss of SHP1 enhances JAK3/STAT3 signaling and decreases proteosome degradation of JAK3 and NPM-ALK in ALK + anaplastic large-cell lymphoma. Blood 2006; 108: 2796-2803.
40. Cimpean AM, Encica S, Raica M, Ribatti D. SOX2 gene expression in normal human thymus and thymoma. Clin Exp Med 2011; 11: 251-254.
41. Loh YH, Agarwal S, Park IH, Urbach A, Huo H, Heffner GC et al. Generation of induced pluripotent stem cells from human blood. Blood 2009; 113: 5476-5479.
42. Eminli S, Foudi A, Stadtfeld M, Maherali N, Ahfeldt T, Mostoslavsky G et al. Differentiation stage determines potential of hematopoietic cells for reprogramming into induced pluripotent stem cells. Nat Genet 2009; 41: 968-976.
43. Jeong CH, Cho YY, Kim MO, Kim SH, Cho EJ, Lee SY et al. Phosphorylation of Sox2 cooperates in reprogramming to pluripotent stem cells. Stem Cells 2010; 28: 2141-2150.
44. Van Hoof D, Munoz J, Braam SR, Pinkse MW, Linding R, Heck AJ et al. Phosphorylation dynamics during early differentiation of human embryonic stem cells. Cell Stem Cell 2009; 5: 214-226.
45. Kamachi Y, Uchikawa M, Kondoh H. Pairing SOX off: with partners in the regulation of embryonic development. Trends Genet 2000; 16: 182-187. (Pubitemid 30169154)
46. Mallanna SK, Ormsbee BD, Iacovino M, Gilmore JM, Cox JL, Kyba M et al. Proteomic analysis of Sox2-associated proteins during early stages of mouse embryonic stem cell differentiation identifies Sox21 as a novel regulator of stem cell fate. Stem Cells 2010; 28: 1715-1727.
47. Fang X, Yoon JG, Li L, Yu W, Shao J, Hua D et al. The SOX2 response program in glioblastoma multiforme: an integrated ChIP-seq, expression microarray, and microRNA analysis. BMC Genomics 2011; 12: 11.
48. Sharov AA, Masui S, Sharova LV, Piao Y, Aiba K, Matoba R et al. Identification of Pou5f1, Sox2, and Nanog downstream target genes with statistical confidence by applying a novel algorithm to time course microarray and genome-wide chromatin immunoprecipitation data. BMC Genomics 2008; 9: 269.
49. Chen YP, Chang KC, Su WC, Chen TY. The expression and prognostic significance of platelet-derived growth factor receptor alpha in mature T-and natural killercell lymphomas. Ann Hematol 2008; 87: 985-990.
50. Jundt F, Anagnostopoulos I, Forster R, Mathas S, Stein H, Dorken B. Activated Notch1 signaling promotes tumor cell proliferation and survival in Hodgkin and anaplastic large cell lymphoma. Blood 2002; 99: 3398-3403. (Pubitemid 34525322)